Biodistribution & Pharmacokinetic of Position Emission Tomography (PET) Radiopharmaceutical 18F C SNAT4
Primary Objectives * Determine the biodistribution of \[18F\]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives * Determine the dosimetry of \[18F\]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. * Determine the acute toxicity of \[18F\]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. * Determine whether uptake in \[18F\]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxon test) before the therapy. * Determine/verify the safety profile of the \[18F\]-C-SNAT4 radiotracer, as an imaging agent in patients with lung cancer. * Determine the time of maximal \[18F\]-C-SNAT4 radiotracer uptake post injection.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 12, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Stanford University
- Interventions being studied
- Drug: 18F-C-SNAT4; Device: Positron emission tomography (PET)/Computed tomography (CT) Scan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- ANC ≥ 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab assessment
- Hgb ≥ 9 g/dL (90 g/L); \< 9 g/dL (\< 90 g/L) is acceptable if Hgb corrected to ≥ 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan
- Platelet count ≥ 100 x 109/L w/o blood transfusions for 7 days preceding lab assessment
- Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for pts with documented history of Gilbert's disease
- ALT ≤ 2.5 x ULN
- AST ≤ 2.5 x ULN
- Alkaline phosphatase (AP) ≤ 3 x ULN
- If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)
- Karnofsky Performance Status (KPS) ≥ 60
- Ability to understand and the willingness to sign a written informed consent document
- Has already begun non-surgical therapy for any recurrence, prior to the first \[18F\]-C-SNAT4 PET/CT scan
- Severe/uncontrolled inter-current illness within the previous 28 days prior to PET scan.
- Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.
- History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biological composition to \[18F\]-C-SNAT4 used in study.
- Pregnant or nursing
- Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford UniversityStanford, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 12, 2026. Always confirm current availability with the study team.